Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men between the ages of 20 and 75
- People who have signed a consent form showing they understand what the study involves and are willing to follow its rules and requirements
- People who have been diagnosed with a specific type of prostate cancer called adenocarcinoma, confirmed through a tissue sample (biopsy)
- People whose prostate cancer is considered high-risk and locally advanced, meaning at least one of the following applies: the tumour has grown beyond the prostate (based on a physical exam or MRI scan); a lab score called the Gleason score is 8 or higher (also called Grade Group 4); or a blood marker called PSA is 20 ng/ml or higher
- People who are willing to have their prostate surgically removed (prostatectomy) as the main treatment
- People who are generally well enough to carry out normal daily activities, with little to no physical limitations (referred to medically as ECOG Performance Status 0 or 1)
Who may not be able to join:
- People whose prostate cancer biopsy shows a rare type of cancer, such as small cell, ductal, or neuroendocrine carcinoma
- People who have already received hormone therapy, radiation therapy, or chemotherapy for their prostate cancer
- People whose scans show the cancer has spread to other parts of the body (metastasis)
- People who have had another type of cancer within the past 5 years
- People who have experienced certain serious heart or blood vessel problems in the 6 months before starting the study, such as a heart attack, severe chest pain (unstable angina), heart failure with symptoms, a stroke or mini-stroke, a blood clot in the lungs, or serious irregular heart rhythms (note: an uncomplicated blood clot in a leg vein does not automatically exclude someone — confirm with trial site)
- People who are HIV-positive and meet one or more of the following conditions: not currently on strong HIV medication; had a change in HIV medication within the past 6 months; are on HIV medication that may interact with the study drug; have a low immune cell count (CD4 below 350); or have had a serious HIV-related infection in the past 6 months
- People with active or symptomatic hepatitis, chronic liver disease, fluid build-up in the abdomen (ascites), or bleeding problems caused by liver dysfunction
- People with a history of seizures, or conditions that may increase the risk of seizures — including a stroke or mini-stroke, loss of consciousness within the past year, abnormal blood vessel formations in the brain, or certain brain growths causing swelling or pressure
- People with digestive or gut conditions that affect how the body absorbs medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chao-Yuan Huang, MD, PhD, National Taiwan University Hospital
Phone: +886223123456
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathologic outcome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.